Investors / United States / Enavate Sciences
Enavate Sciences
Venture capital · New York, NY, United States · North America
Enavate Sciences invests in and supports the strategic growth of therapeutic and enabling technology companies. It provides capital, personalized attention and strategic growth support to life sciences companies and their existing investors.
Invests inHealthcare & Biotech
In its own wordstherapeuticslife sciencesenabling technologybiotechhealthcare
Your fit with Enavate Sciences
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsEnavate Sciences lists 6 checked portfolio companies on its own site and is named in 2 funding rounds. Its most frequent entry is Series A, 100% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 100% of its companies are based in United States. It invests most often alongside Longitude Capital, Andreessen Horowitz and Ascenta Capital.
Counts come from funding rounds that name Enavate Sciences, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundEnavate Sciences does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 100% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 2 | 0 |
| '26 | 0 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 8th | 6 companies |
| Recent activity | 59th | 1 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 19th | 1 country |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Longitude Capital | 2 |
| Andreessen Horowitz | 1 |
| Ascenta Capital | 1 |
| Canaan | 1 |
| Evolution VC Partners | 1 |
| Forbion | 1 |
| Frazier Life Sciences | 1 |
| Innova Capital Partners | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers6100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Longitude Capital
Compare Enavate Sciences head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Enavate Sciences| Date | Company | Stage |
|---|---|---|
| 16 Dec 2025 | Series A | |
| 5 Nov 2025 | Series A |
Round details for Enavate Sciences
Amounts, full round histories and every co-investor in Enavate Sciences' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
6 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Ambros Therapeutics is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases with a high unmet medical need. | Healthcare & Biotech | Dec 2025Series A | Funding round | |
| The company is developing a treatment for hypertrophic cardiomyopathy | Healthcare & Biotech | Nov 2025Series A | Funding round | |
| Graviton Bioscience is pioneering safe and innovative therapies for patients with fibrotic, autoimmune, and CNS diseases. | Healthcare & Biotech | Portfolio page | ||
| The company develops therapeutic candidates for cancer treatment | Healthcare & Biotech | Portfolio page | ||
| Normunity is developing novel anti-cancer therapies that target the interface of the immune system and the tumor. | Healthcare & Biotech | Portfolio page | ||
| OrsoBio is developing novel approaches to treat patients with severe metabolic disorders, including obesity, diabetes, severe dyslipidemias, MASH, and more. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- enavatesciences.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 5 Nov 2025
- Companies checked
- 6
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Enavate Sciences' profile as data
Pull Enavate Sciences' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/enavatesciences.com
# also
GET /v1/firms/enavatesciences.com/portfolio
GET /v1/firms/enavatesciences.com/coinvestors
GET /v1/firms/enavatesciences.com/news